Atherosclerosis, 70 (1988) 278–280
Elsevier Scientific Publishers Ireland, Ltd.

Author Index (Vol.70)

Ackman, R.G.
Some possible effects on lipid biochemistry of differences in the distribution on glycerol of long-chain $n-3$ fatty acids in the fats of marine fish and marine mammals 171
Akioka, H., see Yamashita, S. 7
Albers, J.J., see Miller, N.E. 275
Alderman, E.L., see Laughton, C.W. 233
Alfthan, G., see Salonen, J.T. 155
Allison, J., see Miller, G.J. 63
Amano, S., see Sasahara, M. 53
Arakawa, K., see Sasaki, J. 175
Asada, Y., Hayashi, T. and Sumiyoshi, A.
Vascular injuries induced by materials released from platelet-rich thrombus in vivo 1
Asai, K., see Naito, M. 273
Avogaro, P., see Crepaldi, G. 115

Bedord, C.J., see Laughton, C.W. 233
Bondjers, G., see Olsson, G. 81
Broadhurst, A., see Miller, G.J. 63

Clavey, V., see Olivier, P. 107
Colombo, A., see Poli, A. 253
Crepaldi, G., Avogaro, P., Descovich, G.C., Di Perri, T., Postiglione, A., Sirtori, C.R., Strano, A., Ventura, S. and Musatti, L.
Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemiaResults of a multicenter trial 115

Demke, D.M., Peters, G.R., Linet, O.I., Metzler, C.M. and Klott, K.A.
Effects of a fish oil concentrate in patients with hypercholesterolemia 73
Descovich, G.C., see Crepaldi, G. 115
Dhamu, S., see Monsalve, M.V. 123
Di Perri, T., see Crepaldi, G. 115

East, C., see Vega, G.L. 131

Fruchart, J.C., see Olivier, P. 107
Funahashi, T., see Nakamura, T. 43
Funaki, C., see Naito, M. 273

Gawryl, M.S., see Langlois, P.F. 95
Gillies, P. and Robinson, C.
Decreased plasma membrane fluidity in the development of atherosclerosis in cholesterol-fed rabbits 161
Greenhalgh, R.M., see Monsalve, M.V. 123
Griffin, B.A., Skinner, E.R. and Maughan, R.J.
Plasma high density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations 165
Grundy, S.M., see Vega, G.L. 131
Gutstein, W.H.
The central nervous system and atherogenesis: endothelial injury 145

Hayase, Y., see Sasahara, M. 53
Hayashi, T., see Asada, Y. 1
Hayashi, T., see Naito, M. 273
Hazama, F., see Sasahara, M. 53
Hirano, K., see Yamashita, S. 7
Hoff, H.F. and O'Neil, J.
Extracts of human atherosclerotic lesions can modify low density lipoproteins leading to enhanced uptake by macrophages 29
Humphries, S.E., see Kessling, A.M. 13
Humphries, S.E., see Monsalve, M.V. 123

Ibayashi, H., see Masumoto, A. 217

Jobsis, J., see Monsalve, M.V. 123

Kako, H., see Yamashita, S. 7
Kantola, M., see Salonen, J.T. 155
Kataoka, H., see Sasahara, M. 53
Kawai, J., see Sasahara, M. 53
Kessling, A.M., Nanjee, M.N., Miller, N.E. and Humphries, S.E.
Variations in the apolipoprotein AI–CIII–AIV gene region and in lecithin:cholesterol acyltransferase concentration are determinants of plasma cholesterol concentrations 13
Kitano, Y., see Nakamura, T. 43
Klott, K.A., see Demke, D.M. 73
Koga, S., see Masumoto, A. 217
Koivisto, P.V.I. and Leinonen, H.
Peripheral arterial disease in heterozygous familial hypercholesterolemia: no difference between patients with and without partial ileal bypass 21
Koo, S.I., see Lee, C.C. 205
Kotecha, S., see Miller, G.J. 63
Kurasawa, T., see Yokoyama, S. 179

Kurup, P.A., see Latha, M.S. 225
Kuzuya, F., see Naito, M. 273
Kuzuya, M., see Naito, M. 273

Langlois, P.F. and Gawryl, M.S.
Detection of the terminal complement complex in patient plasma following acute myocardial infarction 95
Latha, M.S., Vijayammal, P.L. and Kurup, P.A.
Effect of exposure of rats to cigarette smoke on the metabolism of lipids 225
Laughton, C.W., Ruddle, D.L., Bedord, C.J. and Alderman, E.L.
Sera containing elevated nonesterified fatty acids from patients with angiographically documented coronary atherosclerosis cause marked lipid accumulation in cultured human arterial smooth muscle-derived cells 233
Lee, C.C. and Koo, S.I.
Separation of three compositionally distinct subclasses of rat high density lipoproteins by heparin-affinity chromatography 205
Leinonen, H., see Koivisto, P.V.I. 21
Linet, O.I., see Demke, D.M. 73

Mäenpää, P.H., see Salonen, J.T. 155
Marzin, D., see Olivier, P. 107
Masumoto, A., Koga, S., Uchida, E. and Ibayashi, H.
Effects of insulin, dexamethasone and glucagon on the production of apolipoprotein A-I in cultured rat hepatocytes 217
Matsuzawa, Y., see Nakamura, T. 43
Matsuzawa, Y., see Yamashita, S. 7
Maughan, R.J., see Griffin, B.A. 165
Meade, T.W., see Miller, G.J. 63
Metzler, C.M., see Demke, D.M. 73
Miller, G.J., Kotecha, S., Wilkinson, W.H., Wilkes, H., Stirling, Y., Sanders, T.A.B., Broadhurst, A., Allison, J. and Meade, T.W.
Dietary and other characteristics relevant for coronary heart disease in men of Indian, West Indian and European descent in London 63
Miller, N.E., Nanjee, M.N. and Albers, J.J.
Plasma cholesterol, ageing and lecithin:cholesterol acyltransferase 275
Miller, N.E., see Kessling, A.M. 13
Monsalve, M.V., Young, R., Jobsis, J., Wiseman, S.A., Dhamu, S., Powell, J.T., Greenhalgh, R.M. and Humphries, S.E.
DNA polymorphisms of the gene for apolipoprotein B in patients with peripheral arterial disease 123
Musatti, L., see Crepaldi, G. 115

Naito, M., Hayashi, T., Funaki, C., Kuzuya, M., Asai, K. and Kuzuya, F.
Calcium antagonists do not inhibit vascular smooth muscle cell chemotaxis caused by platelet-derived growth factor 273
Nakamura, T., Matsuzawa, Y., Okano, M., Kitano, Y., Funahashi, T., Yamashita, S. and Tarui, S.
Characterization of low-density lipoproteins from patients with recessive X-linked ichthyosis 43
Nanjee, M.N., see Kessling, A.M. 13
Nanjee, M.N., see Miller, N.E. 275

Okano, M., see Nakamura, T. 43
Okazaki, M., see Yamashita, S. 7
Olivier, P., Plancke, M.O., Marzin, D., Clavey, V., Sauzieres, J. and Fruchart, J.C.
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic miceA proposed model for drug screening 107
Olofsson, S.-O., see Olsson, G. 81
Olsson, G., Östlund-Lindquist, A.-M., Bondjers, G., Wiklund, O. and Olofsson, S.-O.
Quantification of plasma lipids and apolipoproteins in British Halflop rabbitsA comparison between normocholesterolemic rabbits, hypercholesterolemic rabbits (modified WHHL rabbits) and rabbits fed an atherogenic diet 81
O'Neil, J., see Hoff, H.F. 29
Östlund-Lindquist, A.-M., see Olsson, G. 81

Paoletti, R., see Poli, A. 253
Parviainen, M., see Salonen, J.T. 155
Peters, G.R., see Demke, D.M. 73
Pignoli, P., see Poli, A. 253
Plancke, M.O., see Olivier, P. 107
Poli, A., Tremoli, E., Colombo, A., Sirtori, M., Pignoli, P. and Paoletti, R.
Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patientsA new model for the quantitation and follow-up of preclinical atherosclerosis in living human subjects 253
Postiglione, A., see Crepaldi, G. 115
Powell, J.T., see Monsalve, M.V. 123

Quig, D.W. and Zilversmit, D.B.
Plasma lipid transfer activity in rabbits: effects of dietary hyperlipidemias 263

Rauramaa, R., see Salonen, J.T. 155
Roberts, D.C.K., see Samman, S. 247
Robinson, C., see Gillies, P. 161
Ruddle, D.L., see Laughton, C.W. 233

Saku, K., see Sasaki, J. 175
Salonen, J.T., Salonen, R., Seppänen, K., Kantola, M., Parviainen, M., Alfthan, G., Mäenpää, P.H., Taskinen, E. and Rauramaa, R.
Relationship of serum selenium and antioxidants to plasma lipoproteins, platelet aggregability and prevalent ischaemic heart disease in Eastern Finnish men 155
Salonen, R., see Salonen, J.T. 155
Samman, S. and Roberts, D.C.K.
The effect of zinc supplements on lipoproteins and copper status 247
Sanders, T.A.B., see Miller, G.J. 63
Sasahara, M., Hazama, F., Amano, S., Hayase, Y., Yukioka, N., Kawai, J. and Kataoka, H.
Effect of hypertension on lysosomal enzyme activities in aortic endothelial cells 53

Sasaki, J., Tanabe, Y., Tanaka, H., Saku, K., Shindo, M. and Arakawa, K.
Elevated levels of HDL_2-cholesterol and apo A-I in national class Japanese male marathon runners 175
Sauzieres, J., see Olivier, P. 107
Seppänen, K., see Salonen, J.T. 155
Shindo, M., see Sasaki, J. 175
Sirtori, C.R., see Crepaldi, G. 115
Sirtori, M., see Poli, A. 253
Skinner, E.R., see Griffin, B.A. 165
Stirling, Y., see Miller, G.J. 63
Strano, A., see Crepaldi, G. 115
Sumiyoshi, A., see Asada, Y. 1

Tanabe, Y., see Sasaki, J. 175
Tanaka, H., see Sasaki, J. 175
Tarui, S., see Nakamura, T. 43
Tarui, S., see Yamashita, S. 7
Taskinen, E., see Salonen, J.T. 155
Tremoli, E., see Poli, A. 253

Uchida, E., see Masumoto, A. 217

Vega, G.L., East, C. and Grundy, S.M.
Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B 131
Ventura, S., see Crepaldi, G. 115
Vijayammal, P.L., see Latha, M.S. 225

Wiklund, O., see Olsson, G. 81
Wilkes, H., see Miller, G.J. 63
Wilkinson, W.H., see Miller, G.J. 63
Wiseman, S.A., see Monsalve, M.V. 123

Yamamoto, A., see Yokoyama, S. 179
Yamashita, S., Matsuzawa, Y., Okazaki, M., Kako, H., Yasugi, T., Akioka, H., Hirano, K. and Tarui, S.
Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity 7
Yamashita, S., see Nakamura, T. 43
Yasugi, T., see Yamashita, S. 7
Yokoyama, S., Yamamoto, A. and Kurasawa, T.
A little more information about aggravation of probucol-induced HDL-reduction by clofibrate 179
Young, R., see Monsalve, M.V. 123
Yukioka, N., see Sasahara, M. 53

Zilversmit, D.B., see Quig, D.W. 263

Atherosclerosis, 70 (1988) 281–284
Elsevier Scientific Publishers Ireland, Ltd.

Subject Index (Vol. 70)

Activated platelets
–, Aortic endothelial injury; [^{3}H]Thymidine incorporation; 'En face' autoradiography, 1
Albumin
–, Apolipoprotein A-I; Insulin; Dexamethasone; Glucagon; Cultured hepatocytes, rat, 217
Analytical ultracentrifugation
–, Hyperalphalipoproteinemia; LDL; HDL; Cholesteryl ester transfer activity deficiency; High-performance liquid chromatography, 7
Antioxidans
–, Ischemic heart disease; Lipoproteins; Platelet aggregability; Selenium, 155
Aorta
–, Atherosclerosis; Calcium; Fluorescence anisotrophy; Membrane fluidity; Plasma membrane; Rabbit, 161
–, Lysosomes; Enzymes, Endothelium; Hypertension, 53
Aortic endothelial injury
–, Activated platelets; [^{3}H]Thymidine incorporation; 'En face' autoradiography, 1
Apo B
–, Atherosclerosis; LDL; Macrophages; Lipid peroxidation, 29
–, DNA polymorphism; Peripheral arterial disease, 123
Apolipoprotein(s)
–, Electroimmunoassay; Hyperlipidemia; LDL receptor deficiency, 81
–, Cholesterol; HDL; HDL subclasses; Plasma, rat, 205
Apolipoprotein A-I
–, Albumin; Insulin; Dexamethasone; Glucagon; Cultured hepatocytes, rat, 217
Apolipoprotein AI–CII–AIV
–, RFLPs; Cholesterol; Lecithin:cholesterol acyltransferase, 13
Apolipoprotein E
–, Atherosclerosis; Cholesterol; HDL subfractions; Serum lipids, 165
Apolipoproteinemia B
–, Lovastatin; Dysbetalipoproteinemia, 131
Arterial wall
–, Hypercholesterolemia; Atherosclerosis; B mode imaging; Non-invasive techniques, 253
Atherogenesis
–, Vasopasm; Central nervous system; Stress, 145
Atherosclerosis
–, Aorta; Calcium; Fluorescence anisotropy; Membrane fluidity; Plasma membrane; Rabbit, 161
–, Apolipoprotein E; Cholesterol; HDL subfractions; Serum lipids, 165
–, Hypercholesterolemia; Arterial wall; B mode imaging; Non-invasive techniques, 253
–, LDL; Apo B; Macrophages; Lipid peroxidation, 29
Atherosclerotic plaque
–, Coronary artery disease; Serum lipids; Tissue culture; Nonesterified fatty acids; Cell proliferation, 233

B mode imaging
–, Hypercholesterolemia; Atherosclerosis; Arterial wall; Non-invasive techniques, 253

Calcium
–, Aorta; Atherosclerosis; Fluorescence anisotrophy; Membrane fluidity; Plasma membrane; Rabbit, 161
Cell proliferation
–, Coronary artery disease; Atherosclerotic plaque; Serum lipids; Tissue culture; Nonesterified fatty acids, 233
Central nervous system
–, Atherogenesis; Vasosplasma; Stress, 145
Cholesterol
–, Apolipoprotein AI–CIII–AIV; RFLPs; Lecithin:cholesterol acyltransferase, 13
–, Apolipoprotein E; Atherosclerosis; HDL subfractions; Serum lipids, 165
–, Apolipoproteins; HDL; HDL subclasses; Plasma, rat, 205
–, Cigarette smoke; Phospholipids; Trigylcerides, HDL; LDL; VLDL; Lipoprotein lipase; Hydroxymethylglutaryl-coenzyme A reductase; Hepatic bile acid, 225
–, Peripheral arterial disease; Familial hypercholesterolemia; Partial ileal bypass; Lipoproteins; Smoking, 21
–, Zinc; Copper; Lipoproteins, 247
Cholesterol sulfate
–, Recessive X-linked ichthyosis; Steroid sulfatase deficiency; Lipoprotein; LDL receptor, 43
Cholesteryl ester transfer activity deficiency
–, Hyperalphalipoproteinemia; LDL; HDL; High-performance liquid chromatography; Analytical ultracentrifugation, 7
Cigarette smoke
–, Cholesterol; Phospholipids; Triglycerides; HDL; LDL; VLDL; Lipoprotein lipase; Hydroxymethylglutaryl-coenzyme A reductase; Hepatic bile acid, 225
Coconut oil
–, Lipid transfer protein; Plasma cholesterol; Time course; Olive oil, 263

0021-9150/88/$03.50 © 1988 Elsevier Scientific Publishers Ireland, Ltd.

Complement
–, Inflammation; Myocardial infarction; Terminal complement complex, 95
Copper
–, Zinc; Cholesterol; Lipoproteins, 247
Coronary artery disease
–, Atherosclerotic plaque; Serum lipids; Tissue culture; Non-esterified fatty acids; Cell proliferation, 233
Coronary heart disease
–, Dietary fats; Ethnic groups; Lipoproteins; Factor VII; Fibrinogen; Platelet count, 63
Cultured hepatocytes, rat
–, Apolipoprotein A-I; Albumin; Insulin; Dexamethasone; Glucagon, 217

DNA polymorphism
–, Apo B; Peripheral arterial disease, 123
Dexamethasone
–, Apolipoprotein A-I; Albumin; Insulin; Glucagon; Cultured hepatocytes, rat, 217
Dietary fats
–, Coronary heart disease; Ethnic groups; Lipoproteins; Factor VII; Fibrinogen; Platelet count, 63
Drug treatment
–, Hyperlipoproteinemia; Nicotinic acid; Triglycerides, 115
Dysbetalipoproteinemia
–, Lovastatin; Apolipoproteinemia B, 131

Electroimmunoassay
–, Apolipoproteins; Hyperlipidemia; LDL receptor deficiency, 91
Endothelium
–, Lysosomes; Enzymes; Aorta; Hypertension, 53
'En face' autoradiography
–, Aortic endothelial injury; Activated platelets; [^{3}H]Thymidine incorporation, 1
Enzymes
–, Lysosomes; Aorta; Endothelium; Hypertension, 53
Ethnic groups
–, Coronary heart disease; Dietary fats; Lipoproteins; Factor VII; Fibrinogen; Plaetlet count, 63

Factor VII
–, Coronary heart disease; Dietary fats; Ethnic groups; Lipoproteins; Fibrinogen; Plaetlet count, 63
Familial hypercholesterolemia
–, Peripheral arterial disease; Partial ileal bypass; Cholesterol; Lipoproteins; Smoking, 21
Fenofibrate
–, Gemfibrozil; Nicotinic acid; Lipoproteins; Gel permeation chormatography; Sequential ultracentrifugation; Hyperlipidemic diets, 107
Fibrinogen
–, Coronary heart disease; Dietary fats; Ethnic groups; Lipoproteins; Factor VII; Platelet count, 63
–, Aorta; Atherosclerosis; Calcium; Membrane fluidity; Plasma membrane; Rabbit, 161

Gel permeation chromatography
–, Fenofibrate; Gemfibrozil; Nicotinic acid; Lipoproteins; Sequential ultracentrifugation; Hyperlipidemic diets, 107
Gemfibrozil
–, Fenofibrate; Nicotinic acid; Lipoproteins; Gel permeation chromatography; Sequential ultracentrifugation; Hyperlipidemic diets, 107
Glucagon
–, Apolipoprotein A-I; Albumin; Insulin; Dexamethasone; Cultured hepatocytes, rat, 217

HDL
–, Apolipoproteins; Cholesterol; HDL subclasses; Plasma, rat, 205
–, Cigarette smoke; Cholesterol; Phospholipids; Triglycerides; LDL; VLDL; Lipoprotein lipase; Hydroxymethylglutaryl-coenzyme A reductase; Hepatic bile acid, 225
–, Hyperalphalipoproteinemia; LDL; Cholesteryl ester transfer activity deficiency; High-performance liquid chromatography; Analytical ultracentrifugation, 7
HDL subclasses
–, Apolipoproteins; Cholesterol; HDL; Plasma, rat, 205
HDL subfractions
–, Apolipoprotein E; Atherosclerosis; Cholesterol; Serum lipids, 165
Hepatic bile acid
–, Cigarette smoke; Cholesterol; Phospholipids; Triglycerides; HDL; LDL; VLDL; Lipoprotein lipase; Hydroxymethylglutaryl-coenzyme A reductase, 225
High density lipoproteins, *see under* HDL
High-performance liquid chromatography
–, Hyperalphalipoproteinemia; LDL; HDL; Cholesteryl ester transfer activity deficiency; Analytical ultracentrifugation, 7
Hydroxymethylglutaryl-coenzyme A reductase
–, Cigarette smoke; Cholesterol; Phospholipids; Triglycerides; HDL; LDL; VLDL; Lipoprotein lipase; Hepatic bile acid, 225
Hyperalphalipoproteinemia
–, LDL; HDL; Cholesteryl ester transfer activity deficiency; High-performance liquid chromatography; Analytical ultracentrifugation, 7
Hypercholesterolemia
–, Atherosclerosis; Arterial wall; B mode imaging; Non-invasive techniques, 253.
Hypercholesterolemic patients
–, Lipids; Lipoprotein; MaxEPA; $n-3$ fatty acids; Platelet function, 73
Hyperlipidemia
–, Apolipoproteins; Electroimmunoassay; LDL receptor deficiency, 81
Hyperlipidemic diets
–, Fenofibrate; Gemfibrozil; Nicotinic acid; Lipoproteins; Gel permeation chromatography; Sequential ultracentrifugation, 107
Hyperlipoproteinemia
–, Drug treatment; Nicotinic acid; Triglycerides, 115

Hypertension
–, Lysosomes; Enzymes; Aorta; Endothelium, 53

Inflammation
–, Complement; Myocardial infarction; Terminal complement complex, 95
Insulin
–, Apolipoprotein A-I; Albumin; Dexamethasone; Glucagon; Cultured hepatocytes, rat, 217
Ischemic heart disease
–, Antioxidants; Lipoproteins; Platelet aggregability; Selenium, 155

LDL
–, Atherosclerosis; Apo B; Macrophages; Lipid peroxidation, 29
–, Cigarette smoke; Cholesterol; Phospholipids; Triglycerides; HDL; VLDL; Lipoprotein lipase; Hydroxymethylglutaryl-coenzyme A reductase; Hepatic bile acid, 225
–, Hyperalphalipoproteinemia; HDL; Cholesteryl ester transfer activity deficiency; High-performance liquid chromatography; Analytical ultracentrifugation, 7
LDL receptor
–, Recessive X-linked ichthyosis; Steroid sulfatase deficiency; Cholesterol sulfate; Lipoprotein, 43
LDL receptor deficiency
–, Apolipoproteins; Electroimmunoassay; Hyperlipidemia, 81
Lecithin:cholesterol acyltransferase
–, Apolipoprotein AI–CIII–AIV; RFLPs; Cholesterol, 13
Lipid peroxidation
–, Atherosclerosis; LDL; Apo B; Macrophages, 29
Lipid transfer protein
–, Plasma cholesterol; Time course; Coconut oil; Olive oil, 263
Lipids
–, Hypercholesterolemic patients; Lipoprotein; MaxEPA; $n-3$ fatty acids; Platelet function, 73
Lipoprotein(s)
–, Antioxidants; Ischemic heart disease; Platelet aggregability; Selenium, 155
–, Coronary heart disease; Dietary fats; Ethnic groups; Factor VII; Fibrinogen; Platelet count, 63
–, Fenofibrate; Gemfibrozil; Nicotinic acid; Gel permeation chromatography; Sequential ultracentrifugation; Hyperlipidemic diets, 107, 155
–, Hypercholesterolemic patients; Lipids; MaxEPA; $n-3$ fatty acids; Platelet function, 73
–, Peripheral arterial disease; Familial hypercholesterolemia; Partial ileal bypass; Cholesterol; Smoking, 21
–, Recessive X-linked ichthyosis; Steroid sulfatase deficiency; Cholesterol sulfate; LDL receptor, 43
–, Zinc; Copper; Cholesterol, 247
Lipoprotein lipase
–, Cigarette smoke; Cholesterol; Phospholipids; Triglycerides; HDL; LDL; VLDL; Hydroxymethylglutaryl-coenzyme A reductase; Hepatic bile acid, 225
Lovastatin
–, Dysbetalipoproteinemia; Apolipoproteinemia B, 131
Low density lipoproteins, *see under* LDL
Lysosomes
–, Enzymes; Aorta; Endothelium; Hypertension, 53

Macrophages
–, Atherosclerosis; LDL; Apo B; Lipid peroxidation, 29
MaxEPA
–, Hypercholesterolemic patients; Lipids; Lipoprotein; $n-3$ fatty acids; Platelet function, 73
Membrane fluidity
–, Aorta; Atherosclerosis; Calcium; Fluorescence anisotrophy; Plasma membrane; Rabbit, 161
Myocardial infarction
–, Complement; Inflammation; Terminal complement complex, 95

$n-3$ fatty acids
–, Hypercholesterolemic patients; Lipids; Lipoprotein; MaxEPA; Platelet function, 73
Nicotinic acid
–, Drug treatment; Hyperlipoproteinemia; Triglycerides, 115
–, Fenofibrate; Gemfibrozil; Lipoproteins; Gel permeation chromatography; Sequential ultracentrifugation; Hyperlipidemic diets, 107
Nonesterified fatty acids
–, Coronary artery disease; Atherosclerotic plaque; Serum lipids; Tissue culture; Cell proliferation, 233
Non-invasive techniques
–, Hypercholesterolemia; Atherosclerosis; Arterial wall; B mode imaging, 253

Olive oil
–, Lipid transfer protein; Plasma cholesterol; Time course; Coconut oil, 263

Partial ileal bypass
–, Peripheral arterial disease; Familial hypercholesterolemia; Cholesterol; Lipoproteins; Smoking, 21
Peripheral arterial disease
–, Familial hypercholesterolemia; Partial ileal bypass; Cholesterol; Lipoproteins; Smoking, 21
Peripheral arterial disease
–, Apo B; DNA polymorphism, 123
Phospholipids
–, Cigarette smoke; Cholesterol; Triglycerides; HDL; LDL; VLDL; Lipoprotein lipase; Hydroxymethylglutaryl-coenzyme A reductase; Hepatic bile acid, 225
Plasma cholesterol
–, Lipid transfer protein; Time course; Coconut oil; Olive oil, 263
Plasma membrane
–, Aorta; Atherosclerosis; Calcium; Fluorescence anisotrophy; Membrane fluidity; Rabbit, 161
Plasma, rat
–, Apolipoproteins; Cholesterol; HDL; HDL subclasses, 205
Platelet aggregability
–, Antioxidants; Ischemic heart disease; Lipoproteins; Selenium, 155

Platelet count
–, Coronary heart disease; Dietary fats; Ethnic groups; Lipoproteins; Factor VII; Fibrinogen, 63
Platelat function
–, Hypercholesterolemic patients; Lipids; Lipoprotein; MaxEPA; $n-3$ fatty acids, 73

RFLPs
–, Apolipoprotein AI–CIII–AIV; Cholesterol; Lecithin: cholesterol acyltransferase, 13
Rabbit
–, Aorta; Atherosclerosis; Calcium; Fluorescence anisotrophy; Membrane fluidity; Plasma membrane, 161
Recessive X-linked ichthyosis
–, Steroid sulfatase deficiency; Cholesterol sulfate; Lipoprotein; LDL receptor, 43

Selenium
–, Antioxidants; Ischemic heart disease; Lipoproteins; Platelet aggregability, 155
Sequential ultracentrifugation
–, Fenofibrate; Gemfibrozil; Nicotinic acid; Lipoproteins; Gel permeation chromatography; Hyperlipidemic diets, 107
Serum lipids
–, Apolipoprotein E; Atherosclerosis; Cholesterol; HDL subfractions, 165
–, Coronary artery disease; Atherosclerotic plaque; Tissue culture; Nonesterified fatty acids; Cell proliferation, 233
Smoking
–, Peripheral arterial disease; Familial hypercholesterolemia; Partial ileal bypass; Cholesterol; Lipoproteins, 21
Steroid sulfatase deficiency
–, Recessive X-linked ichthyosis; Cholesterol sulfate; Lipoprotein; LDL receptor, 43
Stress
–, Atherogenesis; Vasospasm; Central nervous system, 145

Terminal complement complex
–, Complement; Inflammation; Myocardial infarction, 95
[^{3}H]Thymidine incorporation
–, Aortic endothelial injury; Activated platelets; 'En face' autoradiography, 1
Time course
–, Lipid transfer protein; Plasma cholesterol; Coconut oil; Olive oil, 263
Tissue culture
–, Coronary artery disease; Atherosclerotic plaque; Serum lipids; Nonesterified fatty acids; Cell proliferation, 233
Triglycerides
–, Cigarette smoke; Cholesterol; Phospholipids; HDL; LDL; VLDL; Lipoprotein lipase; Hydroxymethylglutaryl-coenzyme A reductase; Hepatic bile acid, 225
–, Drug treatment; Hyperlipoproteinemia; Nicotinic acid, 115

Vasospasm
–, Atherogenesis; Central nervous system; Stress, 145
Very low density lipoproteins, *see under* VLDL
VLDL
–, Cigarette smoke; Cholesterol; Phospholipids; Triglycerides; HDL; LDL; Lipoprotein lipase; Hydroxymethylglutaryl-coenzyme A reductase; Hepatic bile acid, 225

Zinc
–, Copper, Cholesterol; Lipoproteins, 247